{"id":"NCT02981368","sponsor":"Progenics Pharmaceuticals, Inc.","briefTitle":"Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer","officialTitle":"A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients With PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2016-11","primaryCompletion":"2018-07","completion":"2018-07","firstPosted":"2016-12-05","resultsPosted":"2021-08-09","lastUpdate":"2021-08-09"},"enrollment":385,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"18F-DCFPyL Injection","otherNames":["PyL"]},{"type":"DIAGNOSTIC_TEST","name":"PET/CT imaging","otherNames":[]}],"arms":[{"label":"18F-DCFPyL Injection","type":"EXPERIMENTAL"}],"summary":"This study evaluates the safety and diagnostic performance of 18F-DCFPyL Injection in patients with at least high risk prostate cancer who are planned for radical prostatectomy with lymphadenectomy (Cohort A) or in patients with locally recurrent or metastatic disease willing to undergo biopsy (Cohort B).\n\nCohort B is complete and no longer recruiting subjects.","primaryOutcome":{"measure":"Specificity of 18F-DCFPyL PET/CT Imaging to Detect Metastatic Prostate Cancer Within the Pelvic Lymph Nodes Relative to Histopathology in High Risk Prostate Cancer Participants (Cohort A)","timeFrame":"Within 28 days of imaging, radical prostatectomy with pelvic lymph node dissection will occur.","effectByArm":[{"arm":"High Risk Prostate Cancer (Cohort A)","deltaMin":97.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":10,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":268},"commonTop":["dysgeusia","headache","fatigue","diarrhea"]}}